INTS · Intensity Therapeutics, Inc. · Webcasts, Transcripts & Audio
$3.07
-0.01 (-0.32%)
At close · Nov 16
Return incl. dividend (before tax)
Play latest call
Q3 2026 earnings call transcript
Going-concern doubt
— flagged Nov 5, 2026
Substantial doubt about the company's ability to continue as a going concern.
“As of September 30, 2026, our cash and cash equivalents were approximately $8.5 million. Based on our balances in cash and cash equivalents, our ability to continue our operations is dependent on obtaining additional capital, which is not within our control. As a result, we believe there is substantial doubt about our ability to continue as a going concern.”View the 10-Q filed Nov 5, 2026
Market Cap
$10.13M
Shares
3.30M
Volume · Nov 16
4555
Avg daily vol (3M)
22.42K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Intensity Therapeutics, Inc. Webcasts
Earnings calls, investor updates, investor days and conferences for Intensity Therapeutics, Inc. (INTS), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Pull transcripts and briefs through the earnings call transcript API or MCP →
Add these events to your calendar (.ics)
Annual General Meeting
Investor event
2026-12-31
Intensity Therapeutics, Inc. (INTS) December 31, 2026 Annual General Meeting
Scheduled
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-12-31
Intensity Therapeutics, Inc. (INTS) December 31, 2026 Conference
Scheduled
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q3
2026-11-05
Intensity Therapeutics, Inc. (INTS) Q3 2026 Earnings Call Transcript
Positive tone
Invincible 4 breast cancer enrollment and efficacy
Invincible 3 Phase III sarcoma trial restart
Phase II and regulatory pathway planning
Diluted EPS
$-1.09
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-09-11
Intensity Therapeutics, Inc. (INTS) September 11, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q2
2026-08-11
Intensity Therapeutics, Inc. (INTS) Q2 2026 Earnings Call Transcript
Positive tone
Capital and funding
Invincible 3 (Phase III ovarian)
Invincible 4 (TNBC)
Diluted EPS
$-1.11
Audio
Transcript
Slides
8-K10-Q
Annual General Meeting
Investor event
2026-06-16
Intensity Therapeutics, Inc. (INTS) June 16, 2026 Annual General Meeting Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY23 · Q2
2023-08-14
Intensity Therapeutics, Inc. (INTS) Q2 2023 Earnings Call
Diluted EPS
$-35.75
Audio
Transcript
Slides
8-K10-Q
Showing 1–7 of 7 webcasts
Key facts
CIK
1567264
CUSIP
45828J202
13F (30d)
14 filings
14 filers
Visit website
Investor relations